We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
-0.6%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$1.9B
AUM Growth
-$126M
Cap. Flow
+$65.1M
Cap. Flow %
3.43%
Top 10 Hldgs %
54.31%
Holding
63
New
4
Increased
4
Reduced
–
Closed
2

Top Buys

Rank Stock Value
1
CLYM
Climb Bio
CLYM
+$17.3M
2
ITOS
iTeos Therapeutics
ITOS
+$16.4M
3
SYRE icon
Spyre Therapeutics
SYRE
+$15.1M
4
CGEM icon
Cullinan Oncology
CGEM
+$14M
5
REPL icon
Replimune Group
REPL
+$10.7M

Top Sells

Rank Stock Value
1
VKTX icon
Viking Therapeutics
VKTX
+$24.6M
2
LABD icon
Direxion Daily S&P Biotech Bear 3X ETF
LABD
+$2.55M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BDTX icon
51
Black Diamond Therapeutics
BDTX
$96.8M
$2.36M 0.12%
506,000
– –
ABSI icon
52
Absci
ABSI
$1.32B
$2.16M 0.11%
700,000
– –
OBIO icon
53
Orchestra BioMed
OBIO
$238M
$1.94M 0.1%
238,193
– –
ZNTL icon
54
Zentalis Pharmaceuticals
ZNTL
$337M
$1.84M 0.1%
450,000
– –
TARA icon
55
Protara Therapeutics
TARA
$220M
$1.69M 0.09%
811,627
+602,400
+288% +$1.76M
ATRA icon
56
Atara Biotherapeutics
ATRA
$75.5M
$1.41M 0.07%
166,000
– –
BCAB icon
57
BioAtla
BCAB
$5.46M
$940K 0.05%
13,727
– –
MIST icon
58
Milestone Pharmaceuticals
MIST
$138M
$408K 0.02%
309,007
– –
DBVT
59
DBV Technologies
DBVT
$799M
$200K 0.01%
50,000
– –
NUVB.WS
60
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$42.7K ﹤0.01%
266,666
– –
SRZNW icon
61
Surrozen Inc Warrant
SRZNW
$69.7K
$1.11K ﹤0.01%
66,666
– –
LABD icon
62
Direxion Daily S&P Biotech Bear 3X ETF
LABD
$71M
– –
-35,000
Closed -$2.55M
VKTX icon
63
Viking Therapeutics
VKTX
$3.7B
– –
-300,000
Closed -$24.6M
1 2
3

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q2 2024 Portfolio in Review

As of Q2 2024, Boxer Capital held 63 positions worth $1.9B, down 6.2% from $2.02B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Boxer Capital deployed $65.1M of net new capital in Q2 2024, opening 4 new positions and adding to 4 existing holdings. Its largest new stake was Climb Bio: 2,603,190 shares worth $18.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

On the sell side, the most notable exit was Viking Therapeutics, an estimated $24.6M sold.

  • Boxer Capital's largest Q2 2024 buy was Climb Bio: 2,603,190 shares worth $18.5M.
  • Boxer Capital added most to iTeos Therapeutics in Q2 2024, an estimated $16.4M increase.
  • Boxer Capital fully exited Viking Therapeutics in Q2 2024, selling an estimated $24.6M.
  • Boxer Capital's ten largest holdings make up 54% of its $1.9B portfolio in Q2 2024.
  • Boxer Capital opened 4 new positions and closed 2 in Q2 2024.
  • Boxer Capital's portfolio value fell 6.2% quarter-over-quarter to $1.9B.

Based on Boxer Capital's 13F filing for Q2 2024, filed 14 Aug 2024.